Federal Notice: AndersonBrecon, Inc. DBA PCI Pharma Services Applies To Import LSD For Clinical Trials

Estimated reading time: 3–5 minutes

On January 8, 2026, the United States Drug Enforcement Administration (DEA) announced a new application from AndersonBrecon, Inc. DBA PCI Pharma Services. The company, based at 5775 Logistics Parkway, Rockford, Illinois 61109-3608, has requested permission to import a controlled substance.

The controlled substance is lysergic acid diethylamide, also known as LSD. The drug code for LSD is 7315. LSD is classified by the government as a Schedule I drug.

AndersonBrecon, Inc. wants to import LSD only for use in clinical trials. No other activities with LSD are allowed under this application. The company is not allowed to import FDA-approved or non-approved finished dosage forms for commercial sale.

The DEA states that approval for importing will only happen if the company’s activities match what is allowed under United States law, specifically 21 U.S.C. 952(a)(2).

Other companies or people who already make or use LSD in bulk can send comments or objections to the proposed registration. They may also request a hearing. All comments or hearing requests must be submitted by February 9, 2026.

Comments should be sent through the Federal eRulemaking Portal at https://www.regulations.gov. For hearings, requests must be sent to:

  • Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152
  • Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152
  • Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152

The DEA notice was signed by Thomas Prevoznik, Deputy Assistant Administrator.

This public notice appears in the Federal Register, Volume 91, Number 5, on January 8, 2026, pages 724-725. The docket number is DEA-1638.


Legal Disclaimer

This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.